v3.26.1
Inventory - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
May 31, 2026
May 14, 2026
Sep. 26, 2023
Inventory [Line Items]              
Net income $ 97.5 $ 634.8 $ 417.0 $ 875.3      
Cost of sales, excluding amortization and impairment of acquired intangible assets 776.9 605.0 1,437.9 1,234.3      
EMPAVELI and SYFOVRE              
Inventory [Line Items]              
Inventory         $ 712.0    
EMPAVELI and SYFOVRE | Business Combination, Pro Forma Information, Nonrecurring Adjustment, Inventory, Fair Value Adjustment              
Inventory [Line Items]              
Net income 567.5            
Apellis Pharmaceuticals, Inc.              
Inventory [Line Items]              
Inventory           $ 712.0  
Apellis Pharmaceuticals, Inc. | Business Combination, Pro Forma Information, Nonrecurring Adjustment, Inventory, Fair Value Adjustment              
Inventory [Line Items]              
Net income 69.7            
Reata Pharmaceuticals, Inc              
Inventory [Line Items]              
Inventory             $ 1,300.0
Reata Pharmaceuticals, Inc | Business Combination, Pro Forma Information, Nonrecurring Adjustment, Inventory, Fair Value Adjustment              
Inventory [Line Items]              
Net income 133.1 $ 52.5 240.7 $ 103.9      
Reata Pharmaceuticals, Inc | Business Combination, Pro Forma Information, Nonrecurring Adjustment, Inventory, Fair Value Adjustment | Clinical Inventory              
Inventory [Line Items]              
Cost of sales, excluding amortization and impairment of acquired intangible assets $ 37.5   $ 94.3